IGC Pharma Inc. (IGC)
IGC trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 10-KT (us-gaap:Revenues), fiscal year ended 2025-03-31, https://www.sec.gov/Archives/edgar/data/1326205/000118518526000941/0001185185-26-000941-index.htm. Net income: SEC 10-KT (us-gaap:NetIncomeLoss), fiscal year ended 2025-03-31.
Profile
| Field | Value |
|---|---|
| Ticker | IGC on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001326205 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | MD |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $1.3M |
| Net income | -$7.1M |
| Operating income | -$7.4M |
| Net margin | -560.3% |
| Operating margin | -585.8% |
| Revenue growth | -5.5% |
| Cash | $405K |
| Total assets | $8.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 16.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Going Concern The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40, Presentation of Financial Statements Going Concern , which requires the Company to evaluate whether there are conditions or events that raise substantial doubt about its ability to continue as a going concern." | 10-Q 2026-11-06 |
| Cash and burn | $377K cash; operating cash flow -$1.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 116,687,169 (2026-11-03); 92,868,241 a year earlier; 63,734,439 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-01-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | MANOHAR CHOWDHRY & ASSOCIATES, Chennai, India | PCAOB Form AP 2026-03-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2027 2026-09-30 | $328K | -$2.0M | -$1.4M | $377K | $1.6M | $1.3M | 10-Q 2026-11-06 |
| Q1 2027 2026-06-30 | $265K | -$2.9M | -$1.4M | $331K | $2.0M | $1.1M | 10-Q 2026-08-14 |
| Q4 2026 2026-03-31 | $317K | -$2.4M | -$1.2M | $207K | $1.6M | $1.2M | 10-Q 2026-05-15 |
| Q3 2026 2025-12-31 | $350K | -$726K | -$1.2M | $900K | $134K | $1.2M | 10-KT 2026-03-18 |
| Q2 2026 2025-09-30 | $191K | -$1.8M | -$2.1M | $1.1M | $136K | $1.1M | 10-Q 2026-11-06 |
| Q1 2026 2025-06-30 | $328K | -$1.6M | -$1.4M | $454K | $136K | $1.3M | 10-Q 2026-08-14 |
| Q4 2025 2025-03-31 | $330K | -$1.2M | -$730K | $405K | $137K | $1.3M | 10-Q 2026-05-15 |
| Q3 2025 2024-12-31 | $257K | -$1.8M | -$1.3M | $470K | $137K | $1.2M | 10-Q 2025-02-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2026-01-06 |
| Latest annual report FORM 10-KT | 10-KT | 2026-03-18 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-06 |
| Latest current report FORM 8-K | 8-K | 2026-07-14 |
| Latest proxy FORM DEF 14A | DEFA14A | 2026-10-22 |
Source: SEC EDGAR submissions feed, 818 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.0% |
| 1 month | -33.3% |
| 3 months | -37.9% |
| Year to date | -35.7% |
| 1 year | -50.0% |
| From 52-week high | -50.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SHPH | Shuttle Pharmaceuticals Holdings Inc. | $4.24 | -6.40% | $20.2M |
| CPHI | China Pharma Holdings Inc. | $0.4800 | -7.35% | $20.7M |
| CELU | Celularity Inc. | $0.6191 | -1.75% | $20.1M |
| TXMD | TherapeuticsMD Inc. | $1.81 | -3.21% | $20.9M |
| AYTU | Aytu BioPharma Inc. | $1.82 | +1.68% | $19.8M |
| ATOS | Atossa Therapeutics Inc. | $1.93 | -1.53% | $19.3M |
| COCP | Cocrystal Pharma Inc. | $0.9777 | -0.24% | $18.8M |
| LPCN | Lipocine Inc. | $1.66 | -2.92% | $18.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier